The 2014-2015 outbreak of Ebola virus disease (EVD) in West Africa claimed more than 10 thousand lives [1] , and the threat of reemergence remains in this region due to the persistence of Ebola virus (EBOV) in bodily fluids during convalescence [2] . Previous studies have analyzed clinical and virological features during the early stage of an EBOV outbreak and showed that EVD patients mainly suffer from fever and gastrointestinal symptoms and rarely internal and external bleeding [3] . Fatalities among EVD patients were associated with high viral loads, the lack of EBOV-specific immunoglobulin G (IgG) production, and increased circulating levels of multiple proinflammatory cytokines [4] [5] [6] .
Previous studies based on large-scale genome surveillance of EBOV in West Africa demonstrated the origin and early transmission of the virus in this outbreak [7, 8] . A rapid increase in genetic diversity was observed in the middle stage of the outbreak; however, the mutation rate of the virus was determined to be similar to that of previous outbreaks [9, 10] . The genetic features of EBOV in the late stage of the outbreak and the characteristics of virus transmission, mutation, and selection were unclear.
In this study, we report a systematic analysis of the clinical, immunological, and virological features of EVD during the period ranging January-March 2015, the late stage of the outbreak. Clinical manifestations and outcomes were correlated with antibody profiles, cytokine levels, and virus evolution. Our findings contribute toward understanding of the key variables associated with clinical outcomes and provide insight into the pathogenesis and evolution of EBOV.
METHODS
All suspected EVD cases for which a sample had been sent to the China Mobile Lab Testing Team (CMLTT) from January 16 to March 10, 2015, were included in this study. A standardized World Health Organization (WHO) case investigation form was obtained for each case. Ebola virus disease diagnosis was confirmed according to the disease definition provided by the WHO, along with laboratory testing [3] . The definitive clinical outcomes for all of the cases were obtained from the Sierra Leone Ministry of Health and Sanitation.
RNA was extracted from all of the samples and subjected to quantitative reverse transcription PCR (qRT-PCR) testing according to a protocol from a previous study [11] . Ebola virus Glycoprotein (GP)-specific immunoglobulins (IgG and immunoglobulin M [IGM]) were detected using a standard enzyme-linked immunosorbent assay (ELISA) commercial kit. The levels of serum interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12p70 (IL-12p70), and interleukin 17 (IL-17), and the IL-1 receptor antagonist (IL-1RA), monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1α (MIP-1α), macrophage inflammatory protein 1β (MIP-1β), interferon-inducible protein 10 (IP-10), regulated-on-activation normal T-cell-expressed and -secreted factor (RANTES), growth-regulated protein α (Gro-α), interferon γ (IFN-γ), and tumor necrosis factor α (TNF-α) were determined using cytokine ELISA kits in accordance with the manufacturer's instructions.
The EBOV-positive RNA samples were subjected to RT-PCR. The amplified products were pooled and sequenced using the next-generation sequencing technique on an Ion Proton machine, as described previously [9] . Raw reads were quality filtered and Newbler 2.9 software was used for assembling the genome sequences with the reference strain (GenBank accession no. KJ660346). The newly sequenced viral genomes were aligned with previously released EBOV genome sequences in Sierra Leone using MAFFT v7.221 software. Phylogenetic analyses were performed using BEAST v1.8.2 (100 million steps with first 25% as burn-in), MrBayes v3.2.5 (cutoff standard deviation of 0.01) and RAxML v8.2.4 (1000 bootstrap replicates) software, with the GTRGAMMA model of nucleotide substitution.
This study was approved by the Ethical Committee of the State Key Laboratory of Pathogen and Biosecurity. These activities were covered by the agreement between the governments of China and Sierra Leone and were under the charge of the Sierra Leone Ministry of Health and Sanitation. All newly sequenced genome sequences have been submitted to GenBank as accession number KY426684-KY426733. Table 1) ; among these, clinical information that included outcomes was available for 62 EVD cases, and this revealed an overall fatality rate of 46.8% (n = 29/62) (Supplementary Table 2 ). For the EVD patients who died, symptoms of vomiting or nausea, diarrhea, jaundice, and hemorrhage were observed significantly more frequently than for those patients who recovered (Supplementary Table 2 ).
Kinetics of Ebola Virus RNA and Immunoglobulin G/Immunoglobulin M
Sixty-five confirmed cases were enrolled for antibody testing, but only 44 confirmed cases were included in cytokine analysis, with 35 non-EVD cases being included as controls (Supplementary Figure 1) . Viral RNA was detected in all EVD cases at the onset of symptoms, and viral RNA levels peaked at day 3 ( Figure 1A ). Patients with EVD developed Ebola Gp-specific IgG responses at the onset of symptoms, with increasing levels of IgG antibody being detected during the disease course. The highest IgG antibody titers of 1:125 000 were observed at days 10-16 after onset, whereas weak IgM responses with the highest titer of 1:2500 were detected around 6-17 days. Importantly, the IgG levels or viral loads in the patients that survived and those that were fatally infected were similar in the first week. However, after day 7, fatal cases exhibited a significantly higher viral load and lower IgG responses compared with patients who survived ( Figure 1B ).
Serum Levels of Inflammatory Cytokines
Positive correlations between cytokine levels and viral loads were observed for IL-1RA, IL-8, IL-10, MIP-1α, MCP-1, and IP-10 (Supplementary Figure 2) . These cytokines presented different temporal patterns between survivors, fatal EVD cases, and patients with unknown infections (Supplementary Figure 3) . Unlike the other 2 groups, survivors displayed decreased levels of IL-17, MCP1, IP-10, and IL-8. During the first week after the onset of symptoms, the levels of IL-8, IP-10, and MCP-1 in fatal EVD cases were higher than in the other groups (P < .05). Seven days after the onset of fever, IL-8 in the survivor group had declined to normal levels, similar to those observed in the unknown infection control group (Supplementary Figure 4) . However, IP-10, MCP-1, and IL-1RA were detected at high levels in the fatal cases. Interestingly, significantly lower production of IL-1β, IL-8, IL-10, IL-12p70, MIP-1α, and TNF-α was observed in the survivor group compared with the fatal and control groups.
Converged Clade With Low Fatality Rate Resulted From Purifying Mutation
Fifty full-length viral genomes were obtained, of which 48 were from the Western Area of Sierra Lione (Figure 2A; Supplementary  Figure 5 ). Phylogenetic analysis demonstrated that 36 (72%) sequences clustered in clade 3.2.4, 6 (12%) sequences clustered in sublineage 3.1.2, and 6 (12%) clustered in sublineage 3.2.5 ( Figure 2 ). Of 36 sequences in lineage 3.2.4, 24 viruses further clustered in a new clade and shared 9 unique mutations. Unlike other lineages or sublineages, the new clade did not possess many sporadic substitutions (Supplementary Figure 5B) . The shared substitutions included 3 synonymous mutations, 2 nonsynonymous mutations (located in NP protein and L protein, respectively), and 4 mutations in the noncoding region (Supplementary Table 3 ). The case fatality rate for this emerging clade prevalent at the late stage of the epidemic (n = 9/23; 39.1%; outcome was unknown for one case) was significantly lower than the overall case fatality rate for EVD cases with sequences and outcomes available by CMLTT (n = 112/201; 62.9%; P = .03) [11] . 
DISCUSSION
The most common symptoms for the 62 confirmed EVD cases analyzed in this study were comparable with those from a previous report in Sierra Leone [11] . The current findings showed that the fatal cases exhibited significantly higher viral loads, lower levels of GP-specific IgG, and higher levels of the cytokines IP-10, MCP-1, and IL-1RA, which implied poor viral clearance and a strong inflammatory response. We also verified that a low fatality rate was associated with a new virus clade identified in our study. Our findings provide insight into the features of EBOV at the late outbreak stage.
EBOV-specific humoral responses play a protective role against viral infection [10] . Our results indicated that EVD cases developed EBOV-specific IgM/IgG responses following the onset of symptoms. Our results revealed that low IgG responses or high viremia in the late stage of infection are important risk factors for a fatal outcome, which was also observed in a previous report by Lanini and colleagues [12] .
In this study, consistent with previous findings, chemokines IP-10, MCP-1, IL-1RA, and MIP-1α and cytokines IL-10, IL-12, and TNF-α were excessively produced in fatal EVD cases, which may be indicative of a cytokine storm resulting in a fatal outcome [13] . Our results demonstrated that only chemokines IP-10, MCP-1, and IL-8 were excessively produced in EVD cases during the early stage of infection, and high levels of IL-1RA, IL-10, IL-12, MIP1-α, IP-10, and MCP-1 during the later stage of EBOV infection were associated with fatal outcomes. These results suggested that fatal outcomes following EBOV infection were more closely associated with the upregulation of cytokines and chemokines during the late stage of infection rather than the early stage of infection, which differed from the results of previous studies that reported recovery from Zaire Ebola infection was associated with early cytokine responses [4, 6] . In addition, increasing IL-8 levels and decreasing RANTES levels were found to be associated with fatal outcomes both in Zaire and Sudan Ebola virus infections, but this was not found in our study or in previous studies of Bundibugyo Ebola virus infections [14] .
Our results suggested that most of the lineages previously prevalent in the same region of the Western Area, Sierra Leone ( Figure 2B ), had diminished by the late outbreak stage, and the resulting viruses tended to converge into a few sublineages, with the majority of cases in the Western Area grouping into sublineage 3.2.4, which could be the consequence of adaptation and purifying selection. A similar phenomenon was identified in a recent study that demonstrated that during the same time period (January-March 2015) 2 major lineages were present, 1 located in the Western Area (namely 3.2.4, as detected in this study), and the other in the east of Sierra Leone (lineage 3.1.2) [15] . The low case fatality rate observed in the new clade may reflect the decreased virulence of the virus and its consequential evasion of surveillance. Fewer sporadic mutations in this new clade imply that this clade might have undergone extensive purifying selection.
Our results showed that the late-stage case fatality rate was lower than that of previous reports, (ie, 73.6% [n= 64/87] and 67.4% [n = 379/563] for the early and middle EVD outbreak stages, respectively, in Sierra Leone) [11] . The mild clinical course and lower fatality rates in the late stage of infection may be due to the lower production of cytokines and chemokines and the less-severe cytokine storm among surviving EVD cases. These mild symptoms and low fatality rates may result from purifying mutations.
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